Moderna stock faces November 6 earnings test after oncology rally

Published on 11/02/2026 at 11:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Moderna stock heads into its November 6 report as investors weigh vaccine sales and oncology progress. Analysts expect a quarterly loss and lower revenue than a year earlier.

What investors watch next

Moderna is scheduled to report third-quarter results before the market opens on Friday, November 6.
Analysts expect a wider quarterly loss than a year earlier and revenue below the prior-year level.

Moderna Inc., US60770K1079, Illustration mit AI erstellt.

Moderna stock is heading toward a key earnings test on Friday, November 6, when the biotechnology company is scheduled to report third-quarter results before the US market opens. MarketBeat said the conference call is scheduled for 8:00 a.m. Eastern time.

Analysts tracked by MarketBeat expect Moderna to post a loss of 1.10 US dollars per share, compared with a loss of 0.51 US dollars in the year-earlier quarter. Revenue is projected at 890.25 million US dollars, down from 1.02 billion US dollars a year earlier. That forecast implies pressure on the company’s near-term operating performance even as investors assess the longer-term potential of its messenger RNA platform.

Oncology raises the stakes

The report will arrive after renewed attention on Moderna’s cancer-vaccine pipeline and its broader effort to expand beyond respiratory products. MarketBeat lists immuno-oncology and cancer-related applications among the company’s development areas, while the company’s commercial portfolio includes COVID-19 and RSV vaccines.

The earnings release may therefore matter beyond the headline loss. Investors are likely to focus on vaccine demand, the pace of development spending and management’s comments on the path from clinical programs to future commercial products. Moderna’s last reported quarter, according to MarketBeat, produced a loss of 1.97 US dollars per share and revenue of 145 million US dollars.

Current trading context

Moderna stock traded at 198.86 euros on Lang & Schwarz at 11:36 CET on Monday, November 2. The real-time quote of Moderna stock is available separately.